Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 13, 2020

View Archived Issues

Endothelial cells have functional deficits in progeria

More enhancers suggest more pathogenicity: study

Tarsius opens two phase I/II trials of TRS-01 eye drops

Positive preclinical data presented for QPG-1029

Phase II data for arimoclomol as treatment of sporadic inclusion body myositis

Immunitor presents interim phase III data for hepcortespenlisimut-L in HCC

FASN as a new prognostic biomarker in Wilms' tumor

G-721-0282, novel CHI3L1 ligand with anti-proliferative effects in models of osteosarcoma

Chinese researchers patent PI3K inhibitors

Novartis identifies new NLRP3 inflammasome inhibitors

Japanese investigators synthesize new PTPN11 inhibitors

Hanmi Science describes new FLT3 and/or FLT3 ITD mutant inhibitors

New SNF2L2 inhibitors presented by Epizyme

ApoE, largest genetic risk factor for AD, also affects synucleinopathies

11 potential blockbuster drugs offer hope, threaten budgets

Tumor-targeted siRNA/pDNA dual delivery system reprograms the tumor microenvironment

Paraoxonase 1 gene therapy offers long-term protection against lethal doses of nerve agents in mice

Mucolipin-1 found to be a potential therapeutic target for DMD

Amgen studies AMG-509 in phase I for metastatic CRPC

PsiOxus initiates phase I study of NG-641 in metastatic or advanced epithelial tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...